Figures & data
Table I. Baseline characteristics of patients included in the analysis.
Table II. Dose intensity, omissions and reductions of cetuximab by worst rash grade by day 28.
Table III. Mean change scores from baseline for physical function and global health status with wild-type Kras.
Table IV. Proportion of patients experiencing deterioration from baseline scores for physical function and global health status in patients with wild-type Kras.